Lineage conversion in pediatric B-cell precursor acute leukemia under blinatumomab therapy
A Semchenkova, E Mikhailova, A Komkov… - International Journal of …, 2022 - mdpi.com
We report incidence and deep molecular characteristics of lineage switch in 182 pediatric
patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were …
patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were …
Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: What level of …
P Merli, M Ifversen, TH Truong, HV Marquart… - Frontiers in …, 2021 - frontiersin.org
Minimal residual disease (MRD) assessment plays a central role in risk stratification and
treatment guidance in paediatric patients with acute lymphoblastic leukaemia (ALL). As …
treatment guidance in paediatric patients with acute lymphoblastic leukaemia (ALL). As …
Relative expansion of CD19‐negative very‐early normal B‐cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and …
E Mikhailova, A Semchenkova… - British Journal of …, 2021 - Wiley Online Library
CD19‐directed treatment in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL)
frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry …
frequently leads to the downmodulation of targeted antigens. As multicolour flow cytometry …
Reliable flow-cytometric approach for minimal residual disease monitoring in patients with B-cell precursor acute lymphoblastic leukemia after CD19-targeted therapy
E Mikhailova, O Illarionova, A Komkov, E Zerkalenkova… - Cancers, 2022 - mdpi.com
Simple Summary We aimed to develop an antibody panel and data analysis algorithm for
multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease …
multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease …
Recognizing minor leukemic populations with monocytic features in mixed-phenotype acute leukemia by flow cell sorting followed by cytogenetic and molecular …
A Semchenkova, E Zerkalenkova, I Demina… - International Journal of …, 2023 - mdpi.com
Mixed-phenotype acute leukemia (MPAL), a rare and heterogeneous category of acute
leukemia, is characterized by cross-lineage antigen expression. Leukemic blasts in MPAL …
leukemia, is characterized by cross-lineage antigen expression. Leukemic blasts in MPAL …
Prognostic value of cross‐lineage expression of the myeloid‐associated antigens CD13 and CD33 in adult B‐lymphoblastic leukemia: A large real‐world study of …
H Liao, H Lai, J Chen, X Shuai, X Zhang… - Cancer …, 2023 - Wiley Online Library
Background Cross‐lineage expression of the myeloid‐associated antigens CD13/CD33 is
common in adult B‐lymphoblastic leukemia (B‐ALL) patients, yet its prognostic value is still …
common in adult B‐lymphoblastic leukemia (B‐ALL) patients, yet its prognostic value is still …
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell …
C Tecchio, A Russignan, M Krampera - Frontiers in Oncology, 2023 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a survival benefit to
adult patients affected by acute lymphoblastic leukemia (ALL). However, to avoid an overt …
adult patients affected by acute lymphoblastic leukemia (ALL). However, to avoid an overt …
Рекомендации по определению минимальной остаточной болезни методом проточной цитометрии при остром В-лимфобластном лейкозе в условиях …
ЕВ Михайлова, ОИ Илларионова… - … и иммунопатологии в …, 2023 - hemoncim.com
Аннотация Многоцветная проточная цитометрия широко используется в современной
лабораторной практике для определения минимальной остаточной болезни (МОБ) у …
лабораторной практике для определения минимальной остаточной болезни (МОБ) у …
[HTML][HTML] Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19 …
E Mikhailova, O Illarionova, L Shelikhova… - …, 2022 - ncbi.nlm.nih.gov
Implementation of CD19 targeting with the bispecific engager blinatumomab and T cells
harboring chimeric antigen receptor (CAR-T) has resulted in significant improvement in …
harboring chimeric antigen receptor (CAR-T) has resulted in significant improvement in …
Flow cell sorting followed by PCR‐based clonality testing may assist in questionable diagnosis and monitoring of acute lymphoblastic leukemia
A Semchenkova, V Zhogov… - International Journal …, 2023 - Wiley Online Library
Introduction Multicolor flow cytometry (MFC) has highly reliable and flexible algorithms for
diagnosis and monitoring of acute lymphoblastic leukemia (ALL). However, MFC analysis …
diagnosis and monitoring of acute lymphoblastic leukemia (ALL). However, MFC analysis …